Cagrilintide mechanism studies reveal dual amylin receptor agonism that delays

Survodutide study data shows 18.6% body weight reduction in 48

Phase 2 trial showed 12.5% body weight reduction at 48

Survodutide animal research shows dual GLP-1/glucagon agonism reduces visceral fat

Survodutide in vitro research shows dual GLP-1/glucagon agonism improves hepatic

Survodutide pharmacology studies reveal dual GLP-1/glucagon receptor agonism drives 15-20%

Survodutide dose response research shows dose-dependent weight loss and metabolic

Phase 2 survodutide safety studies show GI events in 40–55%

Clinical trials show survodutide maintains weight loss beyond 48 weeks

Survodutide demonstrates dual GLP-1/glucagon receptor agonism with superior weight loss

Survodutide mechanism studies reveal dual GLP-1/glucagon receptor agonism driving 15.7%

Mazdutide study data reveals dual GLP-1/glucagon receptor agonism delivers 20.6%

Mazdutide demonstrates 20.2% weight reduction in phase 2 trials with

Mazdutide animal research reveals potent dual GLP-1/glucagon agonism driving 30-40%

Mazdutide dose response research demonstrates 15–25% weight reduction at higher

Mazdutide long term studies show sustained weight reduction and metabolic

Phase 2/3 mazdutide trials show 12–24% weight loss with manageable

Mazdutide pharmacology studies reveal dual GLP-1/glucagon receptor agonism that produces

Mazdutide in vitro research reveals dual GLP-1/glucagon receptor agonism mechanisms

Mazdutide comparative studies reveal dual GLP-1/glucagon receptor agonism produces 15–22%

Mazdutide mechanism studies reveal dual GLP-1 and glucagon receptor agonism